{
    "abstract": "Background H7 influenza strains have pandemic potential. AS03-adjuvanted H7N1 A/mallard/Netherlands/12/2000 split-virion vaccine formulations were evaluated as model H7-subtype vaccine and tested after H7N9 emerged in China, and caused severe human disease with high mortality. Methods In this phase I/II, observer-blind, randomized trial in US and Canada, 420 healthy adults (21\u201364\u00a0years) were randomized to receive 1 of 4 H7N1 vaccine formulations (3.75 or 7.5\u00a0\u03bcg hemagglutinin adjuvanted with either AS03A or AS03B), 15\u00a0\u03bcg unadjuvanted H7N1 hemagglutinin, or saline placebo, given as 2-dose series. Immunogenicity was assessed using hemagglutination-inhibition (HI) and microneutralization (MN) assays, at day 42 (21\u00a0days post-dose 2), month 6, and month 12 (HI only) for the per-protocol cohorts (398, 379 and 368 participants, respectively). Safety is reported up to month 12. Results Beneficial AS03 adjuvant effect was demonstrated. Committee for Medical Products for Human Use, and Center for Biologics Evaluation and Research (CBER) criteria were met for all adjuvanted formulations at day 42 (H7N1 HI assay); seroprotection (SPR) and seroconversion rates (SCR) were 88.5\u201394.8%, mean geometric increase (MGI) 19.2\u201334.9, and geometric mean titers (GMT) 98.3\u2013180.7. Unadjuvanted H7N1 vaccine did not meet CBER criteria. In adjuvanted groups, antibody titers decreased over time; month 12 SPRs and GMTs were low (2.0\u201318.8% and 8.1\u201312.2). MN antibodies showed similar kinetics, with titers persisting at higher range than HI at month 6. All adjuvanted groups showed cross-reactivity against H7N9, with HI responses similar to H7N1. The most frequent solicited symptom in adjuvanted groups was injection site pain (71.2\u201386.7%); grade 3 solicited symptoms were infrequent. Nine participants reported 17 serious adverse events; none were considered causally related to vaccination. Conclusions Adjuvanted H7N1 vaccine formulations had an acceptable safety profile and induced an antibody response after 2 doses with cross-reactivity to H7N9. ClinicalTrials.gov: NCT01934127",
    "author_highlights": [
        {
            "endOffset": 18833,
            "sentence": "Adjuvanted H7N1 vaccine formulations had a clinically acceptable safety profile.",
            "startOffset": 18753
        },
        {
            "endOffset": 18917,
            "sentence": "Beneficial AS03 adjuvant effect was demonstrated for all adjuvanted vaccine groups.",
            "startOffset": 18834
        },
        {
            "endOffset": 18999,
            "sentence": "Post-dose 2, all adjuvanted H7N1 formulations met regulatory acceptance criteria.",
            "startOffset": 18918
        },
        {
            "endOffset": 19081,
            "sentence": "Regulatory acceptance criteria were not met after 1 adjuvanted H7N1 vaccine dose.",
            "startOffset": 19000
        },
        {
            "endOffset": 19130,
            "sentence": "Cross-reactivity to the H7N9 virus was observed.",
            "startOffset": 19082
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Isabella",
                    "initial": "I.",
                    "last": "Monne"
                },
                {
                    "first": "Alice",
                    "initial": "A.",
                    "last": "Fusaro"
                },
                {
                    "first": "Martha I.",
                    "initial": "M.I.",
                    "last": "Nelson"
                },
                {
                    "first": "Lebana",
                    "initial": "L.",
                    "last": "Bonfanti"
                },
                {
                    "first": "Paolo",
                    "initial": "P.",
                    "last": "Mulatti"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Hughes"
                },
                {
                    "first": "Pablo R.",
                    "initial": "P.R.",
                    "last": "Murcia"
                },
                {
                    "first": "Alessia",
                    "initial": "A.",
                    "last": "Schivo"
                },
                {
                    "first": "Viviana",
                    "initial": "V.",
                    "last": "Valastro"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Moreno"
                },
                {
                    "first": "Edward C.",
                    "initial": "E.C.",
                    "last": "Holmes"
                },
                {
                    "first": "Giovanni",
                    "initial": "G.",
                    "last": "Cattoli"
                }
            ],
            "doi": "10.1128/JVI.03181-13",
            "firstpage": "4375",
            "issn": "0022538X",
            "lastpage": "4388",
            "pmid": "24501401",
            "pub_year": 2014,
            "title": "Emergence of a highly pathogenic Avian influenza virus from a low-pathogenic progenitor",
            "volume": "88"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Ron A.M.",
                    "initial": "R.A.M.",
                    "last": "Fouchier"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Schneeberger"
                },
                {
                    "first": "Frans W.",
                    "initial": "F.W.",
                    "last": "Rozendaal"
                },
                {
                    "first": "Jan M.",
                    "initial": "J.M.",
                    "last": "Broekman"
                },
                {
                    "first": "Stiena A.G.",
                    "initial": "S.A.G.",
                    "last": "Kemink"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Munstert"
                },
                {
                    "first": "Thijs",
                    "initial": "T.",
                    "last": "Kuikent"
                },
                {
                    "first": "Guus F.",
                    "initial": "G.F.",
                    "last": "Rimmelzwaan"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Schutten"
                },
                {
                    "first": "Gerard J.J.",
                    "initial": "G.J.J.",
                    "last": "Van Doornum"
                },
                {
                    "first": "Guus",
                    "initial": "G.",
                    "last": "Koch"
                },
                {
                    "first": "Arnold",
                    "initial": "A.",
                    "last": "Bosman"
                },
                {
                    "first": "Marion",
                    "initial": "M.",
                    "last": "Koopmans"
                },
                {
                    "first": "Albert D.M.E.",
                    "initial": "A.D.M.E.",
                    "last": "Osterhaust"
                }
            ],
            "doi": "10.1073/pnas.0308352100",
            "firstpage": "1356",
            "issn": "00278424",
            "lastpage": "1361",
            "pmid": "14745020",
            "pub_year": 2004,
            "title": "Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome",
            "volume": "101"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Hirst"
                },
                {
                    "first": "Caroline R.",
                    "initial": "C.R.",
                    "last": "Astell"
                },
                {
                    "first": "Malachi",
                    "initial": "M.",
                    "last": "Griffith"
                },
                {
                    "first": "Shaun M.",
                    "initial": "S.M.",
                    "last": "Coughlin"
                },
                {
                    "first": "Michelle",
                    "initial": "M.",
                    "last": "Moksa"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Zeng"
                },
                {
                    "first": "Duane E.",
                    "initial": "D.E.",
                    "last": "Smailus"
                },
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Holt"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Jones"
                },
                {
                    "first": "Marco A.",
                    "initial": "M.A.",
                    "last": "Marra"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Petric"
                },
                {
                    "first": "Mel",
                    "initial": "M.",
                    "last": "Krajden"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Lawrence"
                },
                {
                    "first": "Annie",
                    "initial": "A.",
                    "last": "Mak"
                },
                {
                    "first": "Ron",
                    "initial": "R.",
                    "last": "Chow"
                },
                {
                    "first": "Danuta M.",
                    "initial": "D.M.",
                    "last": "Skowronski"
                },
                {
                    "first": "S. Aleina",
                    "initial": "S.A.",
                    "last": "Tweed"
                },
                {
                    "first": "Swee Han",
                    "initial": "S.H.",
                    "last": "Goh"
                },
                {
                    "first": "Robert C.",
                    "initial": "R.C.",
                    "last": "Brunham"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Robinson"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Bowes"
                },
                {
                    "first": "Ken",
                    "initial": "K.",
                    "last": "Sojonky"
                },
                {
                    "first": "Sean K.",
                    "initial": "S.K.",
                    "last": "Byrne"
                },
                {
                    "first": "Yan",
                    "initial": "Y.",
                    "last": "Li"
                },
                {
                    "first": "Darwyn",
                    "initial": "D.",
                    "last": "Kobasa"
                },
                {
                    "first": "Tim",
                    "initial": "T.",
                    "last": "Booth"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Paetzel"
                }
            ],
            "doi": "10.3201/eid1012.040743",
            "firstpage": "2192",
            "issn": "10806040",
            "lastpage": "2195",
            "pmid": "15663859",
            "pub_year": 2004,
            "title": "Novel avian influenza H7N3 strain outbreak, British Columbia",
            "volume": "10"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Marion",
                    "initial": "M.",
                    "last": "Koopmans"
                },
                {
                    "first": "Berry",
                    "initial": "B.",
                    "last": "Wilbrink"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Conyn"
                },
                {
                    "first": "Gerard",
                    "initial": "G.",
                    "last": "Natrop"
                },
                {
                    "first": "Hans",
                    "initial": "H.",
                    "last": "Van Der Nat"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Vennema"
                },
                {
                    "first": "Adam",
                    "initial": "A.",
                    "last": "Meijer"
                },
                {
                    "first": "Jim",
                    "initial": "J.",
                    "last": "Van Steenbergen"
                },
                {
                    "first": "Ron",
                    "initial": "R.",
                    "last": "Fouchier"
                },
                {
                    "first": "Albert",
                    "initial": "A.",
                    "last": "Osterhaus"
                },
                {
                    "first": "Arnold",
                    "initial": "A.",
                    "last": "Bosman"
                }
            ],
            "doi": "10.1016/S0140-6736(04)15589-X",
            "firstpage": "587",
            "issn": "01406736",
            "lastpage": "593",
            "pmid": "14987882",
            "pub_year": 2004,
            "title": "Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands",
            "volume": "363"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Rongbao",
                    "initial": "R.",
                    "last": "Gao"
                },
                {
                    "first": "Bin",
                    "initial": "B.",
                    "last": "Cao"
                },
                {
                    "first": "Yunwen",
                    "initial": "Y.",
                    "last": "Hu"
                },
                {
                    "first": "Zijian",
                    "initial": "Z.",
                    "last": "Feng"
                },
                {
                    "first": "Dayan",
                    "initial": "D.",
                    "last": "Wang"
                },
                {
                    "first": "Wanfu",
                    "initial": "W.",
                    "last": "Hu"
                },
                {
                    "first": "Jian",
                    "initial": "J.",
                    "last": "Chen"
                },
                {
                    "first": "Zhijun",
                    "initial": "Z.",
                    "last": "Jie"
                },
                {
                    "first": "Haibo",
                    "initial": "H.",
                    "last": "Qiu"
                },
                {
                    "first": "Ke",
                    "initial": "K.",
                    "last": "Xu"
                },
                {
                    "first": "Xuewei",
                    "initial": "X.",
                    "last": "Xu"
                },
                {
                    "first": "Hongzhou",
                    "initial": "H.",
                    "last": "Lu"
                },
                {
                    "first": "Wenfei",
                    "initial": "W.",
                    "last": "Zhu"
                },
                {
                    "first": "Zhancheng",
                    "initial": "Z.",
                    "last": "Gao"
                },
                {
                    "first": "Nijuan",
                    "initial": "N.",
                    "last": "Xiang"
                },
                {
                    "first": "Yinzhong",
                    "initial": "Y.",
                    "last": "Shen"
                },
                {
                    "first": "Zebao",
                    "initial": "Z.",
                    "last": "He"
                },
                {
                    "first": "Yong",
                    "initial": "Y.",
                    "last": "Gu"
                },
                {
                    "first": "Zhiyong",
                    "initial": "Z.",
                    "last": "Zhang"
                },
                {
                    "first": "Yi",
                    "initial": "Y.",
                    "last": "Yang"
                },
                {
                    "first": "Xiang",
                    "initial": "X.",
                    "last": "Zhao"
                },
                {
                    "first": "Lei",
                    "initial": "L.",
                    "last": "Zhou"
                },
                {
                    "first": "Xiaodan",
                    "initial": "X.",
                    "last": "Li"
                },
                {
                    "first": "Shumei",
                    "initial": "S.",
                    "last": "Zou"
                },
                {
                    "first": "Ye",
                    "initial": "Y.",
                    "last": "Zhang"
                },
                {
                    "first": "Xiyan",
                    "initial": "X.",
                    "last": "Li"
                },
                {
                    "first": "Lei",
                    "initial": "L.",
                    "last": "Yang"
                },
                {
                    "first": "Junfeng",
                    "initial": "J.",
                    "last": "Guo"
                },
                {
                    "first": "Jie",
                    "initial": "J.",
                    "last": "Dong"
                },
                {
                    "first": "Qun",
                    "initial": "Q.",
                    "last": "Li"
                },
                {
                    "first": "Libo",
                    "initial": "L.",
                    "last": "Dong"
                },
                {
                    "first": "Yun",
                    "initial": "Y.",
                    "last": "Zhu"
                },
                {
                    "first": "Tian",
                    "initial": "T.",
                    "last": "Bai"
                },
                {
                    "first": "Shiwen",
                    "initial": "S.",
                    "last": "Wang"
                },
                {
                    "first": "Pei",
                    "initial": "P.",
                    "last": "Hao"
                },
                {
                    "first": "Weizhong",
                    "initial": "W.",
                    "last": "Yang"
                },
                {
                    "first": "Yanping",
                    "initial": "Y.",
                    "last": "Zhang"
                },
                {
                    "first": "Jun",
                    "initial": "J.",
                    "last": "Han"
                },
                {
                    "first": "Hongjie",
                    "initial": "H.",
                    "last": "Yu"
                },
                {
                    "first": "Dexin",
                    "initial": "D.",
                    "last": "Li"
                },
                {
                    "first": "George F.",
                    "initial": "G.F.",
                    "last": "Gao"
                },
                {
                    "first": "Guizhen",
                    "initial": "G.",
                    "last": "Wu"
                },
                {
                    "first": "Yu",
                    "initial": "Y.",
                    "last": "Wang"
                },
                {
                    "first": "Zhenghong",
                    "initial": "Z.",
                    "last": "Yuan"
                },
                {
                    "first": "Yuelong",
                    "initial": "Y.",
                    "last": "Shu"
                }
            ],
            "doi": "10.1056/NEJMoa1304459",
            "firstpage": "1888",
            "issn": "00284793",
            "lastpage": "1897",
            "pub_year": 2013,
            "title": "Human infection with a novel avian-origin",
            "volume": "368"
        },
        "b0030": null,
        "b0035": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Jonges"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Meijer"
                },
                {
                    "first": "R. A.",
                    "initial": "R.A.",
                    "last": "Fouchier"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Koch"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Li"
                },
                {
                    "first": "J. C.",
                    "initial": "J.C.",
                    "last": "Pan"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Chen"
                },
                {
                    "first": "Y. L.",
                    "initial": "Y.L.",
                    "last": "Shu"
                },
                {
                    "first": "M. P.",
                    "initial": "M.P.",
                    "last": "Koopmans"
                }
            ],
            "issn": "1025496X",
            "pmid": "23611030",
            "pub_year": 2013,
            "title": "Guiding outbreak management by the use of influenza a(H7NX) virus sequence analysis",
            "volume": "18"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Robert B.",
                    "initial": "R.B.",
                    "last": "Couch"
                },
                {
                    "first": "Shital M.",
                    "initial": "S.M.",
                    "last": "Patel"
                },
                {
                    "first": "Chianti L.",
                    "initial": "C.L.",
                    "last": "Wade-Bowers"
                },
                {
                    "first": "Diane",
                    "initial": "D.",
                    "last": "Ni\u00f1o"
                }
            ],
            "doi": "10.1371/journal.pone.0049704",
            "issn": "19326203",
            "pmid": "23239968",
            "pub_year": 2012,
            "title": "A Randomized Clinical Trial of an Inactivated Avian Influenza A (H7N7) Vaccine",
            "volume": "7"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Rebecca J.",
                    "initial": "R.J.",
                    "last": "Cox"
                },
                {
                    "first": "Abdullah S.",
                    "initial": "A.S.",
                    "last": "Madhun"
                },
                {
                    "first": "Solveig",
                    "initial": "S.",
                    "last": "Hauge"
                },
                {
                    "first": "Haakon",
                    "initial": "H.",
                    "last": "Sjursen"
                },
                {
                    "first": "Diane",
                    "initial": "D.",
                    "last": "Major"
                },
                {
                    "first": "Mirjam",
                    "initial": "M.",
                    "last": "Kuhne"
                },
                {
                    "first": "Katja",
                    "initial": "K.",
                    "last": "H\u00f6schler"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Saville"
                },
                {
                    "first": "Frederick R.",
                    "initial": "F.R.",
                    "last": "Vogel"
                },
                {
                    "first": "Wendy",
                    "initial": "W.",
                    "last": "Barclay"
                },
                {
                    "first": "Isabella",
                    "initial": "I.",
                    "last": "Donatelli"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Zambon"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Wood"
                },
                {
                    "first": "Lars R.",
                    "initial": "L.R.",
                    "last": "Haaheim"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.01.116",
            "firstpage": "1889",
            "issn": "0264410X",
            "lastpage": "1897",
            "pmid": "19368768",
            "pub_year": 2009,
            "title": "A phase I clinical trial of a PER.C6\u00ae cell grown influenza H7 virus vaccine",
            "volume": "27"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Kiseleva"
                },
                {
                    "first": "Anatoly N.",
                    "initial": "A.N.",
                    "last": "Naykhin"
                },
                {
                    "first": "Marianna",
                    "initial": "M.",
                    "last": "Erofeeva"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Stukova"
                },
                {
                    "first": "Svetlana",
                    "initial": "S.",
                    "last": "Donina"
                },
                {
                    "first": "Galina",
                    "initial": "G.",
                    "last": "Petukhova"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Pisareva"
                },
                {
                    "first": "Vera",
                    "initial": "V.",
                    "last": "Krivitskaya"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Grudinin"
                },
                {
                    "first": "Zhanna",
                    "initial": "Z.",
                    "last": "Buzitskaya"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Isakova-Sivak"
                },
                {
                    "first": "Svetlana",
                    "initial": "S.",
                    "last": "Kuznetsova"
                },
                {
                    "first": "Natalie",
                    "initial": "N.",
                    "last": "Larionova"
                },
                {
                    "first": "Julia",
                    "initial": "J.",
                    "last": "Desheva"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Dubrovina"
                },
                {
                    "first": "Alexandra",
                    "initial": "A.",
                    "last": "Nikiforova"
                },
                {
                    "first": "John C.",
                    "initial": "J.C.",
                    "last": "Victor"
                },
                {
                    "first": "Kathy",
                    "initial": "K.",
                    "last": "Neuzil"
                },
                {
                    "first": "Jorge",
                    "initial": "J.",
                    "last": "Flores"
                },
                {
                    "first": "Vadim",
                    "initial": "V.",
                    "last": "Tsvetnitsky"
                },
                {
                    "first": "Oleg",
                    "initial": "O.",
                    "last": "Kiselev"
                }
            ],
            "doi": "10.1371/journal.pone.0087962",
            "issn": "19326203",
            "pmid": "24533064",
            "pub_year": 2014,
            "title": "Assessment of human immune responses to H7 avian influenza virus of pandemic potential: Results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine",
            "volume": "9"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Tara M.",
                    "initial": "T.M.",
                    "last": "Babu"
                },
                {
                    "first": "Min",
                    "initial": "M.",
                    "last": "Levine"
                },
                {
                    "first": "Theresa",
                    "initial": "T.",
                    "last": "Fitzgerald"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Luke"
                },
                {
                    "first": "Mark Y.",
                    "initial": "M.Y.",
                    "last": "Sangster"
                },
                {
                    "first": "Hong",
                    "initial": "H.",
                    "last": "Jin"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Topham"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Katz"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Treanor"
                },
                {
                    "first": "Kanta",
                    "initial": "K.",
                    "last": "Subbarao"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.09.070",
            "firstpage": "6798",
            "issn": "0264410X",
            "lastpage": "6804",
            "pmid": "25446831",
            "pub_year": 2014,
            "title": "Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine",
            "volume": "32"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Mahdee",
                    "initial": "M.",
                    "last": "Sobhanie"
                },
                {
                    "first": "Yumiko",
                    "initial": "Y.",
                    "last": "Matsuoka"
                },
                {
                    "first": "Sinthujan",
                    "initial": "S.",
                    "last": "Jegaskanda"
                },
                {
                    "first": "Theresa",
                    "initial": "T.",
                    "last": "Fitzgerald"
                },
                {
                    "first": "Raburn",
                    "initial": "R.",
                    "last": "Mallory"
                },
                {
                    "first": "Zhongying",
                    "initial": "Z.",
                    "last": "Chen"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Luke"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Treanor"
                },
                {
                    "first": "Kanta",
                    "initial": "K.",
                    "last": "Subbarao"
                }
            ],
            "doi": "10.1093/infdis/jiv526",
            "firstpage": "922",
            "issn": "00221899",
            "lastpage": "929",
            "pmid": "26655841",
            "pub_year": 2016,
            "title": "Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9)",
            "volume": "213"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Isakova-Sivak"
                },
                {
                    "first": "Anatoly",
                    "initial": "A.",
                    "last": "Naykhin"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Kiseleva"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "Stukova"
                },
                {
                    "first": "Mariana",
                    "initial": "M.",
                    "last": "Erofeeva"
                },
                {
                    "first": "Daniil",
                    "initial": "D.",
                    "last": "Korenkov"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Matyushenko"
                },
                {
                    "first": "Erin",
                    "initial": "E.",
                    "last": "Sparrow"
                },
                {
                    "first": "Marie Paule",
                    "initial": "M.P.",
                    "last": "Kieny"
                }
            ],
            "doi": "10.1016/S1473-3099(15)00378-3",
            "firstpage": "303",
            "issn": "14733099",
            "lastpage": "310",
            "pmid": "26673391",
            "pub_year": 2016,
            "title": "H7N9 live attenuated influenza vaccine in healthy adults: A randomised, double-blind, placebo-controlled, phase 1 trial",
            "volume": "16"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Anuradha",
                    "initial": "A.",
                    "last": "Madan"
                },
                {
                    "first": "Nathan",
                    "initial": "N.",
                    "last": "Segall"
                },
                {
                    "first": "Murdo",
                    "initial": "M.",
                    "last": "Ferguson"
                },
                {
                    "first": "Louise",
                    "initial": "L.",
                    "last": "Frenette"
                },
                {
                    "first": "Robin",
                    "initial": "R.",
                    "last": "Kroll"
                },
                {
                    "first": "Damien",
                    "initial": "D.",
                    "last": "Friel"
                },
                {
                    "first": "Jyoti",
                    "initial": "J.",
                    "last": "Soni"
                },
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Li"
                },
                {
                    "first": "Bruce L.",
                    "initial": "B.L.",
                    "last": "Innis"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Schuind"
                }
            ],
            "doi": "10.1093/infdis/jiw414",
            "firstpage": "1717",
            "issn": "00221899",
            "lastpage": "1727",
            "pmid": "27609809",
            "pub_year": 2016,
            "title": "Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults",
            "volume": "214"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Louis F.",
                    "initial": "L.F.",
                    "last": "Fries"
                },
                {
                    "first": "Gale E.",
                    "initial": "G.E.",
                    "last": "Smith"
                },
                {
                    "first": "Gregory M.",
                    "initial": "G.M.",
                    "last": "Glenn"
                }
            ],
            "doi": "10.1056/NEJMc1313186",
            "firstpage": "2564",
            "issn": "00284793",
            "lastpage": "2566",
            "pub_year": 2013,
            "title": "A recombinant viruslike particle influenza A (H7N9) vaccine",
            "volume": "369"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Jackson"
                },
                {
                    "first": "James D.",
                    "initial": "J.D.",
                    "last": "Campbell"
                },
                {
                    "first": "Sharon E.",
                    "initial": "S.E.",
                    "last": "Frey"
                },
                {
                    "first": "Kathryn M.",
                    "initial": "K.M.",
                    "last": "Edwards"
                },
                {
                    "first": "Wendy A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "Karen L.",
                    "initial": "K.L.",
                    "last": "Kotloff"
                },
                {
                    "first": "Andrea A.",
                    "initial": "A.A.",
                    "last": "Berry"
                },
                {
                    "first": "Irene",
                    "initial": "I.",
                    "last": "Graham"
                },
                {
                    "first": "Robert L.",
                    "initial": "R.L.",
                    "last": "Atmar"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Buddy Creech"
                },
                {
                    "first": "Isaac P.",
                    "initial": "I.P.",
                    "last": "Thomsen"
                },
                {
                    "first": "Shital M.",
                    "initial": "S.M.",
                    "last": "Patel"
                },
                {
                    "first": "Andres F.",
                    "initial": "A.F.",
                    "last": "Gutierrez"
                },
                {
                    "first": "Edwin L.",
                    "initial": "E.L.",
                    "last": "Anderson"
                },
                {
                    "first": "Hana M.",
                    "initial": "H.M.",
                    "last": "El Sahly"
                },
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Hill"
                },
                {
                    "first": "Diana L.",
                    "initial": "D.L.",
                    "last": "Noah"
                },
                {
                    "first": "Abbie R.",
                    "initial": "A.R.",
                    "last": "Bellamy"
                }
            ],
            "doi": "10.1001/jama.2015.7916",
            "firstpage": "237",
            "issn": "00987484",
            "lastpage": "246",
            "pmid": "26197184",
            "pub_year": 2015,
            "title": "Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response a randomized clinical trial",
            "volume": "314"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Mark J.",
                    "initial": "M.J.",
                    "last": "Mulligan"
                },
                {
                    "first": "David I.",
                    "initial": "D.I.",
                    "last": "Bernstein"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Winokur"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Rupp"
                },
                {
                    "first": "Evan",
                    "initial": "E.",
                    "last": "Anderson"
                },
                {
                    "first": "Nadine",
                    "initial": "N.",
                    "last": "Rouphael"
                },
                {
                    "first": "Michelle",
                    "initial": "M.",
                    "last": "Dickey"
                },
                {
                    "first": "Jack T.",
                    "initial": "J.T.",
                    "last": "Stapleton"
                },
                {
                    "first": "Srilatha",
                    "initial": "S.",
                    "last": "Edupuganti"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Spearman"
                },
                {
                    "first": "Dilek",
                    "initial": "D.",
                    "last": "Ince"
                },
                {
                    "first": "Diana L.",
                    "initial": "D.L.",
                    "last": "Noah"
                },
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Hill"
                },
                {
                    "first": "Abbie R.",
                    "initial": "A.R.",
                    "last": "Bellamy"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Mask"
                },
                {
                    "first": "Allison",
                    "initial": "A.",
                    "last": "Beck"
                },
                {
                    "first": "Lilin",
                    "initial": "L.",
                    "last": "Lai"
                },
                {
                    "first": "Nayoka",
                    "initial": "N.",
                    "last": "Rimann"
                },
                {
                    "first": "Colleen",
                    "initial": "C.",
                    "last": "Kelley"
                },
                {
                    "first": "Melinda",
                    "initial": "M.",
                    "last": "Ogilvie"
                },
                {
                    "first": "Eileen",
                    "initial": "E.",
                    "last": "Osinski"
                },
                {
                    "first": "Dawn",
                    "initial": "D.",
                    "last": "Battle"
                },
                {
                    "first": "Andres",
                    "initial": "A.",
                    "last": "Camacho-Gonzalez"
                },
                {
                    "first": "Anita",
                    "initial": "A.",
                    "last": "McElroy"
                },
                {
                    "first": "Andi",
                    "initial": "A.",
                    "last": "Shane"
                },
                {
                    "first": "Larry",
                    "initial": "L.",
                    "last": "Anderson"
                },
                {
                    "first": "Kathy",
                    "initial": "K.",
                    "last": "Stephens"
                },
                {
                    "first": "Brooke",
                    "initial": "B.",
                    "last": "Hartwell"
                },
                {
                    "first": "Teresa",
                    "initial": "T.",
                    "last": "Ball"
                },
                {
                    "first": "Laila",
                    "initial": "L.",
                    "last": "Hussani"
                },
                {
                    "first": "Theda",
                    "initial": "T.",
                    "last": "Gibson"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Johnson"
                },
                {
                    "first": "Bethany",
                    "initial": "B.",
                    "last": "Sederdahl"
                },
                {
                    "first": "Natasha",
                    "initial": "N.",
                    "last": "Mann"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Frenck"
                },
                {
                    "first": "Rebecca",
                    "initial": "R.",
                    "last": "Brady"
                },
                {
                    "first": "Tara",
                    "initial": "T.",
                    "last": "Foltz"
                },
                {
                    "first": "Amy",
                    "initial": "A.",
                    "last": "Cline"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "McCartney"
                },
                {
                    "first": "Margery",
                    "initial": "M.",
                    "last": "Huron"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Meier"
                },
                {
                    "first": "Margo",
                    "initial": "M.",
                    "last": "Schilling"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Wagner"
                },
                {
                    "first": "Geraldine",
                    "initial": "G.",
                    "last": "Dull"
                },
                {
                    "first": "Kathy",
                    "initial": "K.",
                    "last": "Flanders"
                },
                {
                    "first": "Dan",
                    "initial": "D.",
                    "last": "Zhao"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Reidy"
                },
                {
                    "first": "Gretchen",
                    "initial": "G.",
                    "last": "Cress"
                },
                {
                    "first": "Nikki",
                    "initial": "N.",
                    "last": "Gerot"
                },
                {
                    "first": "Diane",
                    "initial": "D.",
                    "last": "Barrett"
                },
                {
                    "first": "Carrie",
                    "initial": "C.",
                    "last": "Harrington"
                },
                {
                    "first": "Amy",
                    "initial": "A.",
                    "last": "McMahan"
                },
                {
                    "first": "Marianne",
                    "initial": "M.",
                    "last": "Shafer"
                },
                {
                    "first": "Lori",
                    "initial": "L.",
                    "last": "Simon"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Taggart"
                },
                {
                    "first": "Valerie",
                    "initial": "V.",
                    "last": "Johnson"
                },
                {
                    "first": "Donna",
                    "initial": "D.",
                    "last": "Bowen"
                },
                {
                    "first": "Shixiong",
                    "initial": "S.",
                    "last": "Li"
                },
                {
                    "first": "Candi",
                    "initial": "C.",
                    "last": "Looney"
                },
                {
                    "first": "Megan",
                    "initial": "M.",
                    "last": "May"
                },
                {
                    "first": "Rachel",
                    "initial": "R.",
                    "last": "May"
                },
                {
                    "first": "Lawanda",
                    "initial": "L.",
                    "last": "Parker"
                },
                {
                    "first": "Bridgette",
                    "initial": "B.",
                    "last": "Myers"
                },
                {
                    "first": "Nertaissa",
                    "initial": "N.",
                    "last": "Cochran"
                },
                {
                    "first": "Michelle",
                    "initial": "M.",
                    "last": "Bell"
                },
                {
                    "first": "Logan",
                    "initial": "L.",
                    "last": "Haller"
                },
                {
                    "first": "Claire",
                    "initial": "C.",
                    "last": "Stablein"
                },
                {
                    "first": "Sara",
                    "initial": "S.",
                    "last": "Marshall"
                },
                {
                    "first": "Megan",
                    "initial": "M.",
                    "last": "McDonough"
                },
                {
                    "first": "Fenhua",
                    "initial": "F.",
                    "last": "He"
                },
                {
                    "first": "Kuo",
                    "initial": "K.",
                    "last": "Guo"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Lambert"
                },
                {
                    "first": "Wendy",
                    "initial": "W.",
                    "last": "Buchanan"
                },
                {
                    "first": "Valerie",
                    "initial": "V.",
                    "last": "Riddle"
                },
                {
                    "first": "Suzanne",
                    "initial": "S.",
                    "last": "Murray"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Gorman"
                }
            ],
            "doi": "10.1001/jama.2014.12854",
            "firstpage": "1409",
            "issn": "00987484",
            "lastpage": "1419",
            "pmid": "25291577",
            "pub_year": 2014,
            "title": "Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant a randomized clinical trial",
            "volume": "312"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Stephan A.",
                    "initial": "S.A.",
                    "last": "Bart"
                },
                {
                    "first": "Matthew",
                    "initial": "M.",
                    "last": "Hohenboken"
                },
                {
                    "first": "Giovanni",
                    "initial": "G.",
                    "last": "Della Cioppa"
                },
                {
                    "first": "Vas",
                    "initial": "V.",
                    "last": "Narasimhan"
                },
                {
                    "first": "Philip R.",
                    "initial": "P.R.",
                    "last": "Dormitzer"
                },
                {
                    "first": "Niranjan",
                    "initial": "N.",
                    "last": "Kanesa-thasan"
                }
            ],
            "doi": "10.1126/scitranslmed.3008761",
            "issn": "19466234",
            "pmid": "24786323",
            "pub_year": 2014,
            "title": "A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults",
            "volume": "6"
        },
        "b0095": null,
        "b0100": null,
        "b0105": null,
        "b0110": {
            "authors": [
                {
                    "first": "Isabel",
                    "initial": "I.",
                    "last": "Leroux-Roels"
                },
                {
                    "first": "Astrid",
                    "initial": "A.",
                    "last": "Borkowski"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Vanwolleghem"
                },
                {
                    "first": "Mamadou",
                    "initial": "M.",
                    "last": "Dram\u00e9"
                },
                {
                    "first": "Fr\u00e9d\u00e9ric",
                    "initial": "F.",
                    "last": "Clement"
                },
                {
                    "first": "Eliane",
                    "initial": "E.",
                    "last": "Hons"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Devaster"
                },
                {
                    "first": "Geert",
                    "initial": "G.",
                    "last": "Leroux-Roels"
                }
            ],
            "doi": "10.1016/S0140-6736(07)61297-5",
            "firstpage": "580",
            "issn": "01406736",
            "lastpage": "589",
            "pmid": "17707753",
            "pub_year": 2007,
            "title": "Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial",
            "volume": "370"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Risi"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Caldwell"
                },
                {
                    "first": "Larry",
                    "initial": "L.",
                    "last": "Gilderman"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Berwald"
                },
                {
                    "first": "Charles",
                    "initial": "C.",
                    "last": "Fogarty"
                },
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Poling"
                },
                {
                    "first": "Dennis",
                    "initial": "D.",
                    "last": "Riff"
                },
                {
                    "first": "Mira",
                    "initial": "M.",
                    "last": "Baron"
                },
                {
                    "first": "Louise",
                    "initial": "L.",
                    "last": "Frenette"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Sheldon"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Collins"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Shepard"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Dionne"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Brune"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Ferguson"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Vaughn"
                },
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Li"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Fries"
                }
            ],
            "doi": "10.1093/infdis/jir172",
            "firstpage": "1729",
            "issn": "00221899",
            "lastpage": "1738",
            "pmid": "21606531",
            "pub_year": 2011,
            "title": "Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: A phase III, placebo-controlled, randomized study",
            "volume": "203"
        }
    },
    "body_text": [
        {
            "endOffset": 27639,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Blood samples were taken at day 0, 21, 42 and month 6 and 12.",
            "startOffset": 27578,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 28857,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Virus neutralization by serum antibodies was determined by a MN assay on heat-treated sera (56 \u00b0C for 30 min); sera were assessed in single tests (no duplicates).",
            "startOffset": 28695,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 34712,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "SPR, SCR and MGI were low at 6 and 12 months (Table 1).",
            "startOffset": 34657,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 45098,
            "parents": [],
            "secId": "s0100",
            "sentence": "All authors had full access to the data and gave final approval before submission.",
            "startOffset": 45016,
            "title": "Authors contribution"
        },
        {
            "endOffset": 24575,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice guidelines.",
            "startOffset": 24424,
            "title": "Study design and participants"
        },
        {
            "endOffset": 41451,
            "parents": [],
            "secId": "s0085",
            "sentence": "Overall, all formulations were well tolerated.",
            "startOffset": 41405,
            "title": "Discussion"
        },
        {
            "endOffset": 36283,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The most common solicited injection site symptom was pain, which occurred at a higher frequency in the vaccine groups; incidences of injection site pain were also noticeably higher in the adjuvanted vaccine groups than in the H7N1-15 group (Fig. 4A).",
            "startOffset": 36033,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 27457,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "Hemagglutination-inhibition (HI) immune response to the vaccine strain and vaccine-heterologous H7N9 strain up to month 12, and of vaccine-strain and vaccine-heterologous H7N9 microneutralization (MN) antibodies up to month 6 was described.",
            "startOffset": 27217,
            "title": "Study objectives"
        },
        {
            "endOffset": 25247,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "The vaccine formulations contained 3.75 \u03bcg HA adjuvanted with AS03A (H7N1-3.75A) or AS03B (H7N1-3.75B), or 7.5 \u03bcg HA adjuvanted with AS03A (H7N1-7.5A) or AS03B (H7N1-7.5B), or 15 \u03bcg plain antigen (H7N1-15).",
            "startOffset": 25041,
            "title": "Randomization"
        },
        {
            "endOffset": 26469,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The vaccines or placebo (0.5 mL per dose) were administered intramuscularly in the deltoid region of the arm.",
            "startOffset": 26360,
            "title": "Study vaccine"
        },
        {
            "endOffset": 25700,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "The trial was conducted in an observer-blind manner; participants, those responsible for evaluation of any study endpoint, and the sponsor were unaware of the administered product.",
            "startOffset": 25520,
            "title": "Blinding"
        },
        {
            "endOffset": 30409,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "Potential immune-mediated diseases (pIMDs) and serious adverse events (SAEs) were recorded throughout the study.",
            "startOffset": 30297,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 32030,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "SPR was defined as percentage of participants with HI titer \u2a7e1:40.",
            "startOffset": 31964,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 39281,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 39280,
                    "startOffset": 39277
                }
            },
            "secId": "s0085",
            "sentence": "Similarly, after 2-dose administration of inactivated subunit H7N7 vaccine formulations containing up to 90 \u03bcg HA, only 1 vaccinee out of 25 developed a \u2a7e4-fold HI antibody response and final titer of \u2a7e1:40; only 5 vaccinees had an MN titer \u2a7e1:40 [8].",
            "startOffset": 39030,
            "title": "Discussion"
        },
        {
            "endOffset": 27549,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "Safety of the different vaccine formulation between day 42 and month 12 was also evaluated.",
            "startOffset": 27458,
            "title": "Study objectives"
        },
        {
            "endOffset": 23345,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 23179,
                    "startOffset": 23173
                },
                "b0045": {
                    "endOffset": 23179,
                    "startOffset": 23173
                },
                "b0050": {
                    "endOffset": 23179,
                    "startOffset": 23173
                },
                "b0055": {
                    "endOffset": 23243,
                    "startOffset": 23236
                },
                "b0060": {
                    "endOffset": 23243,
                    "startOffset": 23236
                },
                "b0065": {
                    "endOffset": 23344,
                    "startOffset": 23340
                }
            },
            "secId": "s0005",
            "sentence": "Several H7-subtype inactivated influenza vaccines and H7 live-attenuated influenza vaccines have been tested in clinical trials [8\u201311]: some have been reported to induce strong immune memory [11,12], and modest immunogenicity was observed for an H7N9 live attenuated influenza vaccine candidate [13].",
            "startOffset": 23045,
            "title": "Introduction"
        },
        {
            "endOffset": 38864,
            "parents": [],
            "secId": "s0085",
            "sentence": "After vaccination with two doses of split H7N1 virus vaccine containing 12 or 24 \u03bcg HA, only 21% and 23% of vaccinees had detectable antibodies.",
            "startOffset": 38720,
            "title": "Discussion"
        },
        {
            "endOffset": 26308,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "AS03 is an Adjuvant System containing \u0251-tocopherol and squalene in an oil-in-water emulsion (11.86 mg tocopherol for AS03A and 5.93 mg for AS03B), manufactured by GSK Biologicals.",
            "startOffset": 26129,
            "title": "Study vaccine"
        },
        {
            "endOffset": 41936,
            "parents": [],
            "secId": "s0085",
            "sentence": "Incidences of solicited injection site symptoms were higher in the adjuvanted vaccine groups than in the unadjuvanted and placebo groups, especially for pain, which was the most commonly reported injection site symptom.",
            "startOffset": 41717,
            "title": "Discussion"
        },
        {
            "endOffset": 28123,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Assay specificity was assessed.",
            "startOffset": 28092,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 22270,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 22269,
                    "startOffset": 22264
                },
                "b0020": {
                    "endOffset": 22269,
                    "startOffset": 22264
                }
            },
            "secId": "s0005",
            "sentence": "In 2003, 89 human infections were reported in an H7N7 outbreak in the Netherlands, mainly with mild symptoms except for one fatal case [2,4].",
            "startOffset": 22129,
            "title": "Introduction"
        },
        {
            "endOffset": 34827,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "No clinically meaningful differences in immune response were observed between the 3.75 and 7.5 \u03bcg HA formulations.",
            "startOffset": 34713,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 25509,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "The randomization algorithm used a minimization procedure accounting for center, age (21\u201340 years/41\u201364 years), and receipt of seasonal influenza vaccine in the past 3 years.",
            "startOffset": 25335,
            "title": "Randomization"
        },
        {
            "endOffset": 28091,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Serum pre-treatment procedure was adapted (adding a receptor-destroying enzyme treatment step after horse RBC hemadsorption) to remove nonspecific agglutinins of horse RBC and nonspecific virus inhibitors introduced by the hemadsorption step.",
            "startOffset": 27849,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 24777,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from each participant before any study procedure.",
            "startOffset": 24690,
            "title": "Study design and participants"
        },
        {
            "endOffset": 42567,
            "parents": [],
            "secId": "s0085",
            "sentence": "SAEs were uncommon (reported by 9 participants), and none were considered by the investigators to be causally related to vaccination.",
            "startOffset": 42434,
            "title": "Discussion"
        },
        {
            "endOffset": 42715,
            "parents": [],
            "secId": "s0085",
            "sentence": "Reactogenicity and safety profiles did not vary notably between AS03B and AS03A formulations, or between formulations containing 3.75 vs 7.5 \u03bcg HA.",
            "startOffset": 42568,
            "title": "Discussion"
        },
        {
            "endOffset": 24918,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The study is registered at www.ClinicalTrials.gov (NCT01934127) and available at http://www.gsk-clinicalstudyregister.com (study ID: 115415).",
            "startOffset": 24777,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35393,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "By month 12, H7N9 HI GMTs had fallen back to baseline levels.",
            "startOffset": 35332,
            "title": "Immune response to the cross-reactive H7N9 strain"
        },
        {
            "endOffset": 40839,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 40838,
                    "startOffset": 40834
                }
            },
            "secId": "s0085",
            "sentence": "Results were in similar ranges as those reported for an AS03A-adjuvanted H5N1 vaccine, where SPR and SCR in adults 18\u201364 years of age were 90.8% (95% CI: 89.3%; 92.2%) [23].",
            "startOffset": 40666,
            "title": "Discussion"
        },
        {
            "endOffset": 40255,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 40254,
                    "startOffset": 40244
                },
                "b0080": {
                    "endOffset": 40254,
                    "startOffset": 40244
                },
                "b0085": {
                    "endOffset": 40254,
                    "startOffset": 40244
                },
                "b0090": {
                    "endOffset": 40254,
                    "startOffset": 40244
                }
            },
            "secId": "s0085",
            "sentence": "This finding is in agreement with observations of other H7 vaccine candidates; while adjuvanted low-antigen-content formulations elicit higher immune responses than unadjuvanted high-antigen-content formulations, minimal to no effect of antigen doses is observed within formulations using the same adjuvant [14,16\u201318].",
            "startOffset": 39937,
            "title": "Discussion"
        },
        {
            "endOffset": 33556,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Overall, 420 participants received at least 1 study dose and constituted the TVC; 398 of them were included in the day 42 PP cohort for immunogenicity (Fig. 1).",
            "startOffset": 33396,
            "title": "Study population"
        },
        {
            "endOffset": 40552,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 40551,
                    "startOffset": 40547
                }
            },
            "secId": "s0085",
            "sentence": "Similarly, a study assessing various formulations of adjuvanted and non-adjuvanted H5N1 vaccinations (containing 3.75, 7.5, 15 or 30 \u03bcg HA) in adults 18\u201360 years of age observed no antigen-dose effect on the HI antibody response for adjuvanted formulations after a 2-dose vaccination course [22].",
            "startOffset": 40256,
            "title": "Discussion"
        },
        {
            "endOffset": 32317,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "VRR for MN titers was defined as proportion of participants with either pre-vaccination (Day 0) reciprocal titer <28 and post-vaccination reciprocal titer \u2a7e56, or pre-vaccination reciprocal HI titer \u2a7e28 and \u2a7e4-fold increase in post-vaccination reciprocal titer against the tested virus.",
            "startOffset": 32031,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 41010,
            "parents": [],
            "secId": "s0085",
            "sentence": "Nevertheless, all adjuvanted formulations were immunogenic in both age strata (21\u201340 and 41\u201364 years).",
            "startOffset": 40908,
            "title": "Discussion"
        },
        {
            "endOffset": 43666,
            "parents": [],
            "secId": "s0085",
            "sentence": "Our results show that AS03 adjuvantation elicits robust immunogenicity at antigen-sparing doses and thus represents an avenue for protection against various H7 subtype infections.",
            "startOffset": 43487,
            "title": "Discussion"
        },
        {
            "endOffset": 37981,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Nine participants (2 [3.3%] in the H7N1-3.75B group, 1 [1.7%] in the H7N1-3.75A, H7N1-7.5B and H7N1-15 groups, 1 [1.6%] in the H7N1-7.5A group and 3 [2.5%] in the placebo group) reported 17 SAEs during the study (Supplemental Table 4).",
            "startOffset": 37746,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 31963,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "SCR was defined as percentage of participants with either pre-vaccination titer <1:10 and post-vaccination titer \u2a7e1:40, or pre-vaccination titer \u2a7e1:10 and \u2a7e4-fold increase in post-vaccination titer.",
            "startOffset": 31765,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 38719,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 38718,
                    "startOffset": 38713
                },
                "b0045": {
                    "endOffset": 38718,
                    "startOffset": 38713
                }
            },
            "secId": "s0085",
            "sentence": "Moreover, previously evaluated non-adjuvanted H7 vaccine candidates were found to have poor immunogenicity in humans [8,9].",
            "startOffset": 38596,
            "title": "Discussion"
        },
        {
            "endOffset": 37127,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The incidence of grade 3 solicited general symptoms was low; each grade 3 solicited general symptom was reported by \u2a7d4 (6.7%) participants per group.",
            "startOffset": 36978,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 44410,
            "parents": [],
            "secId": "s0095",
            "sentence": "ES conducted several clinical trials with GSK.",
            "startOffset": 44364,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 44740,
            "parents": [],
            "secId": "s0095",
            "sentence": "The CEO/owner of CRG received payment as per guidelines to present papers at conferences.",
            "startOffset": 44651,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 25334,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "Allocation to groups was performed using an internet-based randomization system (SBIR).",
            "startOffset": 25247,
            "title": "Randomization"
        },
        {
            "endOffset": 32397,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "HI antibody response was also calculated by age stratum (21\u201340 and 41\u201364 years).",
            "startOffset": 32317,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 44120,
            "parents": [],
            "secId": "s0090",
            "sentence": "GlaxoSmithKline Biologicals SA paid for all costs associated with the development and the publishing of the present manuscript.",
            "startOffset": 43993,
            "title": "Funding"
        },
        {
            "endOffset": 34003,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "In adults 21\u201364 years of age, the CBER and CHMP criteria as described in the co-primary objective were met for all adjuvanted formulations at day 42 (21 days post-dose 2) (Fig. 2, Table 1).",
            "startOffset": 33814,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 22491,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 22372,
                    "startOffset": 22369
                },
                "b0030": {
                    "endOffset": 22490,
                    "startOffset": 22487
                }
            },
            "secId": "s0005",
            "sentence": "However, in 2013, a novel avian influenza virus (H7N9) emerged, causing human infections in China [5] with high morbidity and mortality (322 deaths among 800 laboratory-confirmed cases, reported up to November 2016) [6].",
            "startOffset": 22271,
            "title": "Introduction"
        },
        {
            "endOffset": 28192,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "The assay cut-off was 10 (reciprocal of the initial serum dilution).",
            "startOffset": 28124,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 44523,
            "parents": [],
            "secId": "s0095",
            "sentence": "MF declares payment from Colchester Research Group (CRG) for work as an investigator outside the submitted work.",
            "startOffset": 44411,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 27848,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 27847,
                    "startOffset": 27843
                }
            },
            "secId": "s0040",
            "sentence": "Horse red blood cells (RBC) were used because a significantly improved sensitivity to detect HI antibodies was observed for H7 strains [21].",
            "startOffset": 27708,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 25040,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "Participants were randomized (1:1:1:1:1:2) to receive 1 of 5 H7N1 vaccine formulations, or saline placebo.",
            "startOffset": 24934,
            "title": "Randomization"
        },
        {
            "endOffset": 21916,
            "parents": [],
            "secId": "s0005",
            "sentence": "Most H7 influenza viruses are considered marginally pathogenic avian influenza viruses causing only mild disease in birds.",
            "startOffset": 21794,
            "title": "Introduction"
        },
        {
            "endOffset": 33269,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "An adapted PP cohort was defined, which includes day 0, 21 and 42 data obtained from the PP day 42 cohort, month 6 data obtained from the PP month 6 cohort, and month 12 data obtained from the PP month 12 cohort.",
            "startOffset": 33057,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 34656,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Following a peak 21 days post-dose 2 (day 42), HI titers declined at month 6 and further at month 12, but GMTs remained above baseline levels in the adjuvanted groups (month 6: 11.8\u201321.2, month 12: 8.1\u201312.2).",
            "startOffset": 34448,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 41653,
            "parents": [],
            "secId": "s0085",
            "sentence": "Although injection site pain was reported in 71.2\u201386.7% of the participants, incidences of grade 3 pain did not exceed 5% of study participants, and other grade 3 solicited symptoms were also uncommon.",
            "startOffset": 41452,
            "title": "Discussion"
        },
        {
            "endOffset": 35757,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Vaccine-homologous (H7N1) and heterologous (H7N9) MN antibody parameters (seropositivity rates, GMT, and VRR) showed an increase from day 0 to day 42, and then a decrease until month 6 with values remaining above baseline for groups H7N1-3.75B, H7N1-3.75A, H7N1-7.5B, and H7N1-7.5A (Fig. 3).",
            "startOffset": 35466,
            "title": "Vaccine-homologous (H7N1) and heterologous (H7N9) MN antibody profiles"
        },
        {
            "endOffset": 26128,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "Vaccine formulations contained 3.75 or 7.5 \u03bcg HA of the A/mallard/Netherlands/12/2000 NIBRG-63 strain, adjuvanted with AS03A or AS03B.",
            "startOffset": 25994,
            "title": "Study vaccine"
        },
        {
            "endOffset": 39722,
            "parents": [],
            "secId": "s0085",
            "sentence": "There was no clinically meaningful difference between the adjuvant effects of AS03B and AS03A.",
            "startOffset": 39628,
            "title": "Discussion"
        },
        {
            "endOffset": 42337,
            "parents": [],
            "secId": "s0085",
            "sentence": "Until month 12, no participants discontinued participation due to an SAE.",
            "startOffset": 42264,
            "title": "Discussion"
        },
        {
            "endOffset": 36977,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Incidences of joint pain tended to be higher in all vaccinated groups compared to placebo.",
            "startOffset": 36887,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 42433,
            "parents": [],
            "secId": "s0085",
            "sentence": "Unsolicited AEs were reported at similar rates in the various vaccine groups and placebo group.",
            "startOffset": 42338,
            "title": "Discussion"
        },
        {
            "endOffset": 43992,
            "parents": [],
            "secId": "s0090",
            "sentence": "GlaxoSmithKline Biologicals SA was involved in all stages of the study conduct and analysis.",
            "startOffset": 43900,
            "title": "Funding"
        },
        {
            "endOffset": 38522,
            "parents": [],
            "secId": "s0085",
            "sentence": "All adjuvanted formulations were immunogenic, with an acceptable safety profile.",
            "startOffset": 38442,
            "title": "Discussion"
        },
        {
            "endOffset": 40665,
            "parents": [],
            "secId": "s0085",
            "sentence": "CBER and CHMP immunogenicity acceptance criteria were met at 21 days post-dose 2 for all adjuvanted formulations.",
            "startOffset": 40552,
            "title": "Discussion"
        },
        {
            "endOffset": 37611,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "No clinically relevant changes in the laboratory parameters of the participants were observed up to day 42.",
            "startOffset": 37504,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 39936,
            "parents": [],
            "secId": "s0085",
            "sentence": "The study did not show a marked impact of HA content (3.75 vs 7.5 \u03bcg) on immune response.",
            "startOffset": 39847,
            "title": "Discussion"
        },
        {
            "endOffset": 31765,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "A seronegative participant was defined as having an antibody titer below the cut-off value; antibody titers below the cut-off were given an arbitrary value of half the cut-off for GMT calculation.",
            "startOffset": 31569,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 42264,
            "parents": [],
            "secId": "s0085",
            "sentence": "For the other solicited general symptoms, no distinct differences between the vaccinated groups and the placebo group could be observed.",
            "startOffset": 42128,
            "title": "Discussion"
        },
        {
            "endOffset": 39846,
            "parents": [],
            "secId": "s0085",
            "sentence": "There was a trend towards higher MGI for AS03A\u2013adjuvanted formulations compared to AS03B, but the 95% CIs were overlapping.",
            "startOffset": 39723,
            "title": "Discussion"
        },
        {
            "endOffset": 44284,
            "parents": [],
            "secId": "s0095",
            "sentence": "AM, PL, BLI, AS and PR own stock/stock options/restricted shares in GSK.",
            "startOffset": 44212,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 29850,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "MN antibody GMTs, seropositivity rates, and vaccine response rates (VRRs) were evaluated with 95% CIs.",
            "startOffset": 29748,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 41716,
            "parents": [],
            "secId": "s0085",
            "sentence": "Compliance with receipt of two vaccine doses was high (98.3%).",
            "startOffset": 41654,
            "title": "Discussion"
        },
        {
            "endOffset": 43135,
            "parents": [],
            "secId": "s0085",
            "sentence": "Nevertheless, there was a notable increase in immune response from dose 1 to dose 2 for groups receiving adjuvanted formulations, which indicates the induction of a T-cell response.",
            "startOffset": 42954,
            "title": "Discussion"
        },
        {
            "endOffset": 35331,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Cross-reactivity against vaccine-heterologous H7N9 virus was observed by HI assay 21 days post-dose 2 (day 42) and at month 6 in all groups who received an adjuvanted formulation, with HI GMTs ranging from 187.2\u2013421.0 at day 42 and 10.0\u201319.7 at month 6 (Fig. 2, Table 1).",
            "startOffset": 35060,
            "title": "Immune response to the cross-reactive H7N9 strain"
        },
        {
            "endOffset": 28468,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "Antibody geometric mean titers (GMTs), seropositivity rates, mean geometric increase (MGI), seroconversion rate (SCR) and seroprotection rate (SPR) were evaluated with 98.75% confidence intervals (CIs) regarding the primary objective and 95% CIs for the secondary objectives.",
            "startOffset": 28193,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 43486,
            "parents": [],
            "secId": "s0085",
            "sentence": "High cross-reactivity against vaccine-heterologous H7N9 virus was observed by HI assay 21 days post-dose 2, in all adjuvanted groups.",
            "startOffset": 43353,
            "title": "Discussion"
        },
        {
            "endOffset": 36668,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Muscle aches, headache, and fatigue were the most commonly reported solicited general symptoms (Fig. 4B).",
            "startOffset": 36563,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 32637,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "The secondary objective concerning adjuvant effect was met when the lower limit of the 98.75% CI for HI GMT ratio (adjuvanted to non-adjuvanted group) exceeded 1.5 and the SCR difference (adjuvanted minus non-adjuvanted group) exceeded 10%.",
            "startOffset": 32397,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33672,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "413 (98.3%) participants completed the day 42 visit, while 386 (91.9%) participants returned to the month 12 visit.",
            "startOffset": 33557,
            "title": "Study population"
        },
        {
            "endOffset": 29747,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "For the MN assay, titers <28 were considered to be below the cut-off.",
            "startOffset": 29678,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 41145,
            "parents": [],
            "secId": "s0085",
            "sentence": "Immune responses after the first dose were low, indicating the need for a 2-dose vaccination schedule to achieve robust immunogenicity.",
            "startOffset": 41010,
            "title": "Discussion"
        },
        {
            "endOffset": 25897,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "The laboratory was also blinded to the treatment, and individual data were not available during the course of the study to the sponsor, any investigator, or any person involved in data collection.",
            "startOffset": 25701,
            "title": "Blinding"
        },
        {
            "endOffset": 24424,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The studies comprised 7 study visits (day 0, 7, 21, 28, 42, and month 6 and 12), and 2 telephone contacts (month 3 and 9).",
            "startOffset": 24302,
            "title": "Study design and participants"
        },
        {
            "endOffset": 36563,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Incidences of injection site redness and swelling were also low; no participants reported grade 3 redness, and grade 3 swelling was reported for 1 participant (1.7%) in the H7N1-3.75A group.",
            "startOffset": 36373,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 32891,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Immunogenicity analyses were based on the per-protocol (PP) cohorts for immunogenicity (at day 42, month 6, and month 12).",
            "startOffset": 32769,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 37503,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "A total of 16 unsolicited AEs considered by the investigator to be causally related to vaccination were reported by 11 participants (1 [1.7%] in the H7N1-3.75B, H7N1-7.5B and H7N1-15 groups, 2 [3.3%] in the H7N1-3.75A and H7N1-7.5A groups, and 4 [3.3%] in the placebo group) (Supplemental Table 3).",
            "startOffset": 37205,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 40907,
            "parents": [],
            "secId": "s0085",
            "sentence": "As observed with other vaccines, immunogenicity decreased with age.",
            "startOffset": 40840,
            "title": "Discussion"
        },
        {
            "endOffset": 30296,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "Diary cards were used to capture solicited symptoms during the 7-day post-vaccination period and spontaneously reported adverse events (AEs) up to 21 days post-vaccination.",
            "startOffset": 30124,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 28695,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "The assay was performed with A/mallard/Netherlands/12/2000 (vaccine-homologous H7N1 strain; all participants) and A/Shanghai/2/2013 (vaccine-heterologous H7N9 strain; all vaccine recipients and a subset of placebo recipients).",
            "startOffset": 28469,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 33056,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "This included the participants who complied with protocol procedures, had received 2 study doses, and for whom the assay results for H7N1 antibodies were available.",
            "startOffset": 32892,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 38595,
            "parents": [],
            "secId": "s0085",
            "sentence": "Adjuvantation allows antigen sparing, which is key for pandemic vaccines.",
            "startOffset": 38522,
            "title": "Discussion"
        },
        {
            "endOffset": 27031,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "The first secondary objective was to demonstrate adjuvant effect of AS03 for adjuvanted formulations that met CBER/CHMP criteria 21 days post-dose 2.",
            "startOffset": 26882,
            "title": "Study objectives"
        },
        {
            "endOffset": 22128,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 22078,
                    "startOffset": 22075
                },
                "b0010": {
                    "endOffset": 22106,
                    "startOffset": 22103
                },
                "b0015": {
                    "endOffset": 22127,
                    "startOffset": 22124
                }
            },
            "secId": "s0005",
            "sentence": "However, some highly pathogenic viruses evolved from low-pathogenic precursors and caused important avian influenza outbreaks in poultry in Italy (1999\u20132001) [1], the Netherlands (2003) [2] or Canada (2004) [3].",
            "startOffset": 21917,
            "title": "Introduction"
        },
        {
            "endOffset": 23885,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "This study was a phase I/II, observer-blind, randomized, controlled, multi-country study with a staggered dosing scheme (Supplementary methods), conducted in the US and Canada between August 2013 and October 2014.",
            "startOffset": 23672,
            "title": "Study design and participants"
        },
        {
            "endOffset": 23044,
            "parents": [],
            "secId": "s0005",
            "sentence": "Following the emergence of H7N9 human infections and before availability of H7N9 strains for vaccine development, this study was initiated with an AS03-adjuvanted H7N1 strain as a model for H7-subtype influenza vaccines.",
            "startOffset": 22824,
            "title": "Introduction"
        },
        {
            "endOffset": 36005,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "In the adjuvanted groups, VRR values for the homologous H7N1 MN antibody titers were \u2a7e86.7% 21 days post-dose 2 and \u2a7e50% at month 6, while VRR values for H7N9 MN antibody titers were \u2a7e83.3% and 51.9%, respectively, at the same timepoints (Fig. 3).",
            "startOffset": 35758,
            "title": "Vaccine-homologous (H7N1) and heterologous (H7N9) MN antibody profiles"
        },
        {
            "endOffset": 30123,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "Blood samples for clinical safety laboratory (hematology/biochemistry; Supplementary methods) evaluations were drawn at day 0, 7, 21, 28, and 42; an additional blood sample was drawn at the screening visit for participants of step 1.",
            "startOffset": 29890,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 38247,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The 4 non-resolved SAEs were reported by 2 participants: 1 reported anal cancer, while another participant reported ovarian cyst, salpingitis and uterine leiomyoma.",
            "startOffset": 38083,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 39029,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 39028,
                    "startOffset": 39025
                }
            },
            "secId": "s0085",
            "sentence": "While adjuvantation with aluminum hydroxide enhanced the number of responders (50% and 62%, respectively), none of the formulations met CHMP licensing criteria [9].",
            "startOffset": 38865,
            "title": "Discussion"
        },
        {
            "endOffset": 44650,
            "parents": [],
            "secId": "s0095",
            "sentence": "MF\u2019s wife is CEO/owner of CRG and they have conducted numerous clinical trials with multiple sponsors over the last ten years.",
            "startOffset": 44524,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 36886,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Incidences of muscle ache and fatigue tended to be higher in the groups who received an adjuvanted formulation than in those who received the unadjuvanted vaccine or placebo, except for fatigue in the H7N1-7.5B group.",
            "startOffset": 36669,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 25993,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The monovalent H7N1 split-virus vaccine was manufactured by GSK, Quebec, Canada.",
            "startOffset": 25913,
            "title": "Study vaccine"
        },
        {
            "endOffset": 33769,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Baseline characteristics were balanced in the vaccine and placebo groups (Supplementary Table 1).",
            "startOffset": 33672,
            "title": "Study population"
        },
        {
            "endOffset": 24301,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Two doses of vaccine or placebo were administered at day 0 and 21.",
            "startOffset": 24235,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29430,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "After incubation, virus replication was visualized by hemagglutination of RBC added to culture fluids.",
            "startOffset": 29328,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 31568,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "GMT calculations were performed by taking the anti-log of the mean of the log10 transformed inverse titers.",
            "startOffset": 31461,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 44852,
            "parents": [],
            "secId": "s0095",
            "sentence": "AT conducted several clinical trials with GSK as an investigator at Manna Research.",
            "startOffset": 44769,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 27216,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0035",
            "sentence": "Another secondary objective assessed whether unadjuvanted vaccine resulted in an immune response that met or exceeded CBER/CHMP immunogenicity acceptance criteria, 21 days post-dose 2.",
            "startOffset": 27032,
            "title": "Study objectives"
        },
        {
            "endOffset": 37746,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Up to the month 12 visit, no pIMDs were reported, and none of the participants experienced an AE leading to withdrawal from the study.",
            "startOffset": 37612,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 42127,
            "parents": [],
            "secId": "s0085",
            "sentence": "Incidences of fatigue and muscle ache also tended to be higher in the adjuvanted groups generally, and incidences of joint pain tended to be higher in all vaccine groups compared to placebo.",
            "startOffset": 41937,
            "title": "Discussion"
        },
        {
            "endOffset": 31075,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "The type I error was split equally so that if any of the adjuvanted H7N1 vaccines met CBER/CHMP criteria, the co-primary study objective of immunogenicity was considered met.",
            "startOffset": 30901,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 30727,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "The target sample size was 420 participants (60 in each vaccine group and 120 in the placebo group).",
            "startOffset": 30627,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 24089,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Persons eligible for enrolment were healthy men and women 21\u201364 years of age at the time of first study vaccination and satisfying preset inclusion criteria (exclusion criteria in Supplementary methods).",
            "startOffset": 23886,
            "title": "Study design and participants"
        },
        {
            "endOffset": 43352,
            "parents": [],
            "secId": "s0085",
            "sentence": "In conclusion, in the current study in adults 21\u201364 years of age, 2-dose vaccination with AS03-adjuvanted H7N1 vaccine formulations induced a strong humoral immune response with a clinically acceptable safety profile.",
            "startOffset": 43135,
            "title": "Discussion"
        },
        {
            "endOffset": 23424,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 23423,
                    "startOffset": 23416
                },
                "b0075": {
                    "endOffset": 23423,
                    "startOffset": 23416
                },
                "b0080": {
                    "endOffset": 23423,
                    "startOffset": 23416
                },
                "b0085": {
                    "endOffset": 23423,
                    "startOffset": 23416
                },
                "b0090": {
                    "endOffset": 23423,
                    "startOffset": 23416
                }
            },
            "secId": "s0005",
            "sentence": "On the other hand, adjuvantation has shown to increase immunogenicity [14\u201318].",
            "startOffset": 23346,
            "title": "Introduction"
        },
        {
            "endOffset": 42953,
            "parents": [],
            "secId": "s0085",
            "sentence": "Although it has been suggested that the evaluation of cell-mediated immune responses might bring additional information, our analysis focused on endpoints used for CBER and CHMP criteria, which may be a potential limitation of this trial.",
            "startOffset": 42715,
            "title": "Discussion"
        },
        {
            "endOffset": 32768,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Safety analyses were performed on the total vaccinated cohort (TVC), including all participants who received at least 1 study dose.",
            "startOffset": 32637,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 37204,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "At least 1 unsolicited AE was reported by \u2a7d17 (27.9%) participants per group.",
            "startOffset": 37127,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 41405,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 41404,
                    "startOffset": 41400
                },
                "b0110": {
                    "endOffset": 41293,
                    "startOffset": 41289
                }
            },
            "secId": "s0085",
            "sentence": "Likewise, the adjuvanted H5N1 vaccine formulation containing 3.8 \u03bcg HA needed 2 doses to meet CBER and CHMP immunogenicity acceptance criteria [22], and also AS03-adjuvanted H7N9 vaccine formulations require 2 doses to induce an adequate immune response [14].",
            "startOffset": 41146,
            "title": "Discussion"
        },
        {
            "endOffset": 44768,
            "parents": [],
            "secId": "s0095",
            "sentence": "LC has nothing to disclose.",
            "startOffset": 44741,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 44211,
            "parents": [],
            "secId": "s0095",
            "sentence": "AM, DF, JS, PL, BLI and AS are employees of the GSK group of companies.",
            "startOffset": 44140,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 30604,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0045",
            "sentence": "SAEs were defined as any medical occurrence that resulted in death, was life-threatening, resulted in disability or incapacity, or required hospitalization or prolonged existing hospitalization.",
            "startOffset": 30410,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 26359,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The placebo control was phosphate-buffered saline.",
            "startOffset": 26309,
            "title": "Study vaccine"
        },
        {
            "endOffset": 31348,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "According to CBER immunogenicity acceptance criteria, the primary objective was met if the lower limit of the 98.75% CI for SCR met or exceeded 40%, and the lower limit of the 98.75% CI for the incidence rate of HI reciprocal titers \u2a7e40 (potential SPR) met or exceeded 70%.",
            "startOffset": 31075,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 22823,
            "parents": [],
            "secId": "s0005",
            "sentence": "The World Health Organization recognizes development of vaccines as an important aspect of the global strategy for pandemic preparedness.",
            "startOffset": 22686,
            "title": "Introduction"
        },
        {
            "endOffset": 35008,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Analyses of HI antibody response by age stratum showed a trend toward higher HI GMT titers in the younger (21\u201340 years) than older age stratum (41\u201364 years) (Supplementary Table 2).",
            "startOffset": 34827,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 23628,
            "parents": [],
            "secId": "s0005",
            "sentence": "This trial assessed immunogenicity and safety of different vaccine formulations comprising H7N1 split-virus hemagglutinin (HA) antigen (A/mallard/Netherlands/12/2000) with AS03 in adults aged 21\u201364 years.",
            "startOffset": 23424,
            "title": "Introduction"
        },
        {
            "endOffset": 38082,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "None of these SAEs were considered related to vaccination; 13 SAEs resolved by the end of the study.",
            "startOffset": 37982,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 39465,
            "parents": [],
            "secId": "s0085",
            "sentence": "In our study, adjuvant effect of AS03 was demonstrated in all groups; the unadjuvanted formulation containing 15 \u03bcg plain H7N1 antigen did not meet CBER criteria or CHMP SPR criteria.",
            "startOffset": 39282,
            "title": "Discussion"
        },
        {
            "endOffset": 34447,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "At day 21, GMTs were low across all treatment groups (Fig. 2).",
            "startOffset": 34385,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 44363,
            "parents": [],
            "secId": "s0095",
            "sentence": "NS declares receiving funding from GSK for multiple influenza clinical trials.",
            "startOffset": 44285,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 22686,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 22685,
                    "startOffset": 22682
                }
            },
            "secId": "s0005",
            "sentence": "Although there has been no evidence of sustained human-to-human transmission, the genetic changes observed in the H7N9 virus suggest adaptation to mammals, indicating its pandemic potential [7].",
            "startOffset": 22492,
            "title": "Introduction"
        },
        {
            "endOffset": 29179,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "A standardized amount of virus was mixed with serial serum dilutions and incubated to allow antibody binding to the virus.",
            "startOffset": 29057,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 31461,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "CHMP criteria were: point estimate for SCR exceeds 40%, point estimate for SPR exceeds 70%, and MGI exceeds 2.5.",
            "startOffset": 31349,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 38441,
            "parents": [],
            "secId": "s0085",
            "sentence": "We report here the first assessment of an AS03-adjuvanted H7N1 vaccine, developed initially as model H7 vaccine in light of the H7N9 influenza outbreak in China which started in 2013.",
            "startOffset": 38258,
            "title": "Discussion"
        },
        {
            "endOffset": 29327,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "A cell suspension, containing a defined amount of Madin-Darby Canine Kidney cells was then added to the serum/virus mixture and incubated at 37 \u00b0C.",
            "startOffset": 29180,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 36372,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "The incidence of grade 3 injection site pain was low (\u2a7d3 [5.0%] participants per group).",
            "startOffset": 36284,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 29677,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "The neutralizing titer corresponded to the highest serum dilution able to neutralize 50% of the virus; in practice, this titer corresponds to the GMT between the last dilution without haemagglutination (100% neutralization) and the next dilution.",
            "startOffset": 29431,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 30900,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Assuming an enrolment of 60 participants per vaccine group and a non-evaluable rate of 5%, the overall study power to assess the primary immunogenicity endpoint was 88.80%.",
            "startOffset": 30728,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 34261,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Administration of unadjuvanted vaccine did not meet CBER or CHMP SPR criteria at day 42; only the CHMP criteria for SCR and MGI were met (Table 1).",
            "startOffset": 34114,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 24235,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Participants who attended the screening visit (Supplementary methods) had to have results of all safety laboratory tests within reference ranges.",
            "startOffset": 24090,
            "title": "Study design and participants"
        },
        {
            "endOffset": 27707,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "HI antibody titers were measured in serially-diluted serum samples.",
            "startOffset": 27640,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 43899,
            "parents": [],
            "secId": "s0090",
            "sentence": "The trial was funded by the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services (HHS/BARDA; contract number HHSO100200700029C) and GlaxoSmithKline Biologicals SA.",
            "startOffset": 43673,
            "title": "Funding"
        },
        {
            "endOffset": 45015,
            "parents": [],
            "secId": "s0100",
            "sentence": "All authors participated in the design, implementation or analysis, or the interpretation of the study, and the development of this manuscript.",
            "startOffset": 44872,
            "title": "Authors contribution"
        },
        {
            "endOffset": 33369,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0050",
            "sentence": "Statistical analyses were performed using Statistical Analysis System (SAS) version 9.22 on Windows.",
            "startOffset": 33269,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 34113,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The adjuvant effect of AS03 was demonstrated for all adjuvanted vaccine groups, 21 days post-dose 2 (Table 2).",
            "startOffset": 34003,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 39628,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 39627,
                    "startOffset": 39623
                }
            },
            "secId": "s0085",
            "sentence": "Similarly, AS03 adjuvant was shown to enhance the immune response against H7 antigens for antigen-sparing doses of an AS03-adjuvanted H7N9 vaccine candidate [14].",
            "startOffset": 39466,
            "title": "Discussion"
        },
        {
            "endOffset": 29056,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0040",
            "sentence": "The assay was performed for a subset of participants in each study group, with A/mallard/Netherlands/12/2000 as vaccine-homologous strain and with A/Anhui/1/2013 as vaccine-heterologous H7N9 strain.",
            "startOffset": 28858,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 24689,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The protocol was approved by the independent ethics committee or institutional review board of each study center.",
            "startOffset": 24576,
            "title": "Study design and participants"
        },
        {
            "endOffset": 45174,
            "parents": [],
            "secId": "s0100",
            "sentence": "The corresponding author was responsible for submission of the publication.",
            "startOffset": 45099,
            "title": "Authors contribution"
        },
        {
            "endOffset": 34385,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "MGI point estimates tended to be higher for AS03A\u2013adjuvanted formulations than for AS03B, but the 95% CIs were overlapping.",
            "startOffset": 34262,
            "title": "Immune response to the H7N1 vaccine strain"
        },
        {
            "endOffset": 26882,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 26696,
                    "startOffset": 26692
                },
                "b0100": {
                    "endOffset": 26757,
                    "startOffset": 26753
                }
            },
            "secId": "s0035",
            "sentence": "Co-primary objectives were to evaluate whether vaccination with adjuvanted vaccine formulations resulted in an immune response that met or exceeded the Center for Biologics Evaluation and Research (CBER) [19] and Committee for Medical Products for Human Use (CHMP) [20] immunogenicity acceptance criteria, 21 days post-dose 2; and to evaluate safety and reactogenicity through the day 42 visit.",
            "startOffset": 26488,
            "title": "Study objectives"
        }
    ],
    "docId": "S0264410X17301196",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "Anu.2.Madan@gsk.com",
                "first": "Anuradha",
                "initial": "A.",
                "last": "Madan"
            },
            {
                "email": null,
                "first": "Murdo",
                "initial": "M.",
                "last": "Ferguson"
            },
            {
                "email": null,
                "first": "Eric",
                "initial": "E.",
                "last": "Sheldon"
            },
            {
                "email": null,
                "first": "Nathan",
                "initial": "N.",
                "last": "Segall"
            },
            {
                "email": null,
                "first": "Laurence",
                "initial": "L.",
                "last": "Chu"
            },
            {
                "email": "azhar.toma@mannaresearch.com",
                "first": "Azhar",
                "initial": "A.",
                "last": "Toma"
            },
            {
                "email": null,
                "first": "Paul",
                "initial": "P.",
                "last": "Rheault"
            },
            {
                "email": null,
                "first": "Damien",
                "initial": "D.",
                "last": "Friel"
            },
            {
                "email": null,
                "first": "Jyoti",
                "initial": "J.",
                "last": "Soni"
            },
            {
                "email": "ping.li4@pfizer.com",
                "first": "Ping",
                "initial": "P.",
                "last": "Li"
            },
            {
                "email": null,
                "first": "Bruce L.",
                "initial": "B.L.",
                "last": "Innis"
            },
            {
                "email": null,
                "first": "Anne",
                "initial": "A.",
                "last": "Schuind"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.01.054",
        "firstpage": "1431",
        "issn": "0264410X",
        "keywords": [
            "AS03 adjuvant",
            "H7 influenza vaccine",
            "H7N1",
            "H7N9",
            "Pandemic flu"
        ],
        "lastpage": "1439",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial"
    }
}